A high-throughput analysis of novel anti-fibrotics in human adult cardiac fibroblasts

Biomed Pharmacother. 2025 Jul:188:118216. doi: 10.1016/j.biopha.2025.118216. Epub 2025 Jun 3.

Abstract

Myocardial fibrosis, a hallmark of heart failure (HF), contributes to disease progression and mortality by impairing cardiac function. Despite the identification of potential anti-fibrotic molecules, there is a lack of effective pharmacological interventions for cardiac fibrosis due to poor translational relevance and limited clinical success. In vitro culture models using human cardiac fibroblasts (hCF) provide a cost-effective and scalable approach for high-throughput drug screening, particularly when coupled with artificial intelligence (AI)-assisted imaging technologies. In this study, we developed a novel high-throughput 2D screening platform to identify new anti-fibrotic compounds targeting hCF. Using this approach, we have successfully identified novel molecules with potential anti-fibrotic activity, offering new therapeutic avenues for cardiac fibrosis and other fibrotic disorders.

Keywords: Anti-fibrotic drugs; Cardiac fibrosis; High-throughput; Imaging; Myofibroblast.

MeSH terms

  • Antifibrotic Agents* / pharmacology
  • Cells, Cultured
  • Fibroblasts* / drug effects
  • Fibroblasts* / metabolism
  • Fibroblasts* / pathology
  • Fibrosis
  • High-Throughput Screening Assays* / methods
  • Humans
  • Myocardium* / pathology

Substances

  • Antifibrotic Agents